Compare McCormick & Company, Incorporated (MKC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Novo Nordisk A/S — how do they compare? McCormick & Company, Incorporated trades at $52.73 (market cap $14.22B), while Novo Nordisk A/S trades at $45.98 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 14.6× McCormick & Company, Incorporated's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| MKC | NVO | |
|---|---|---|
Market Cap | $14.22B | $207.85B |
Sector | Consumer Staples | Health |
52-Week High | $72.26 | $63.98 |
52-Week Low | $45.60 | $35.29 |
Enterprise Value | $18.82B | $222.55B |
Dividend Yield | 3.63% | 3.81% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
